Akiram Therapeutics to present promising data on the therapeutic potential of its drug candidate at EANM Congress

Akiram Therapeutics to present promising data on the therapeutic potential of its drug candidate at EANM Congress

BySciety Communications

Akiram Therapeutics, a Swedish biotech company specializing in radiotherapy will present promising preclinical data at the European Association of Nuclear Medicine (EANM) Congress taking place in Vienna, Austria on September 9–13. The data showcases the potential of the company’s radiopharmaceutical 177Lu-AKIR001 targeting tumor lesions for therapeutic purposes. A Phase 1 study is planned for 2024….

Akiram Therapeutics raises SEK 68 million for clinical development of a drug candidate for rare thyroid cancers

Akiram Therapeutics raises SEK 68 million for clinical development of a drug candidate for rare thyroid cancers

BySciety Communications

The Swedish radioimmunotherapy company Akiram Therapeutics, developing targeted cancer therapy, has raised SEK 68 million in a share issue led by Sciety and the network Sciety Venture Partners. The investment company Linc AB participated in the share issue with SEK 20 million. The proceeds from the financing will be used for GMP production of the…